Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs

Abstract

Platinum(II)-sulindac complexes [{η -C H SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η -C H SN(O)}PtCl{(S=O)Sulindac}], [{η -C H SN(O)}PtCl{(S=O)Sulindac-succinimide}], and [{η -C H SN(O)}PtCl{(S=O)Sulindac-thymidine}] were synthesized that exhibited IC values of 2.9-4.8 μm against human oral cancer cells OECM1. The poly(lactic-co-glycolic acid) (PLGA) encapsulated [{η -C H SN(O)}PtCl{(S=O)Sulindac}] also showed cytotoxic activity although less potent than the pristine species.

Enantioseparation, Stereochemical Assignment and Chiral Recognition Mechanism of Sulfoxide-Containing Drugs

“…Both 1 and 2 earned enough attention because of marvelous market success, and 3 is a wake-promoting drug used in the war [ 6 , 7 , 8 ]. Recently, the non-steroidal anti-inflammatory drug 4 and its derivatives aroused the interest of researchers for its potent anticancer effect [ 9 , 10 ].…”